Robert joined Brandon Capital in 2021.
Robert has a unique and proven track record in the management of science-based product development programs from the University lab bench, through the biotechnology spin-out path, to sale and integration into a large pharmaceutical company. Most recently, Robert was Director and CEO of Elastagen Pty Ltd, where he led the business from lab bench start up in 2008 to a global operation with a late stage clinical pipeline. Robert led the integration of the business into Allergan following Elastagen’s acquisition for ~A$350M, and again into Abbvie following its acquisition of Allergan.
Robert has a Bachelor of Science (Hons) from the University of Leeds, a PhD from University College London, and a Masters in Entrepreneurship & Innovation from Swinburne University’s Australian Graduate School of Entrepreneurship.